BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 10736216)

  • 1. A condition for successful escape of a mutant after primary HIV infection.
    Monteiro LH; Gonçalves CH; Piqueira JR
    J Theor Biol; 2000 Apr; 203(4):399-406. PubMed ID: 10736216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-HIV adaptive immunity: determinants for viral persistence.
    Yamamoto H; Matano T
    Rev Med Virol; 2008; 18(5):293-303. PubMed ID: 18416450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlates of cytotoxic T-lymphocyte-mediated virus control: implications for immunosuppressive infections and their treatment.
    Wodarz D; Nowak MA
    Philos Trans R Soc Lond B Biol Sci; 2000 Aug; 355(1400):1059-70. PubMed ID: 11186307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling plasma virus concentration during primary HIV infection.
    Stafford MA; Corey L; Cao Y; Daar ES; Ho DD; Perelson AS
    J Theor Biol; 2000 Apr; 203(3):285-301. PubMed ID: 10716909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates of HIV immune escape and reversion: implications for vaccination.
    Davenport MP; Loh L; Petravic J; Kent SJ
    Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.
    Allen TM; O'Connor DH; Jing P; Dzuris JL; Mothé BR; Vogel TU; Dunphy E; Liebl ME; Emerson C; Wilson N; Kunstman KJ; Wang X; Allison DB; Hughes AL; Desrosiers RC; Altman JD; Wolinsky SM; Sette A; Watkins DI
    Nature; 2000 Sep; 407(6802):386-90. PubMed ID: 11014195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine-induced T cells control reversion of AIDS virus immune escape mutants.
    Fernandez CS; Smith MZ; Batten CJ; De Rose R; Reece JC; Rollman E; Venturi V; Davenport MP; Kent SJ
    J Virol; 2007 Apr; 81(8):4137-44. PubMed ID: 17251297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple transmissions of a stable human leucocyte antigen-B27 cytotoxic T-cell-escape strain of HIV-1 in The Netherlands.
    Cornelissen M; Hoogland FM; Back NK; Jurriaans S; Zorgdrager F; Bakker M; Brinkman K; Prins M; van der Kuyl AC
    AIDS; 2009 Jul; 23(12):1495-500. PubMed ID: 19487902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTL escape and increased viremia irrespective of HIV-specific CD4+ T-helper responses in two HIV-infected individuals.
    Geels MJ; Jansen CA; Baan E; De Cuyper IM; van Schijndel GJ; Schuitemaker H; Goudsmit J; Pollakis G; Miedema F; Paxton WA; van Baarle D
    Virology; 2006 Feb; 345(1):209-19. PubMed ID: 16246391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTL ontogeny and viral escape: implications for HIV-1 vaccine design.
    Yang OO
    Trends Immunol; 2004 Mar; 25(3):138-42. PubMed ID: 15036041
    [No Abstract]   [Full Text] [Related]  

  • 11. Evolution and transmission of stable CTL escape mutations in HIV infection.
    Goulder PJ; Brander C; Tang Y; Tremblay C; Colbert RA; Addo MM; Rosenberg ES; Nguyen T; Allen R; Trocha A; Altfeld M; He S; Bunce M; Funkhouser R; Pelton SI; Burchett SK; McIntosh K; Korber BT; Walker BD
    Nature; 2001 Jul; 412(6844):334-8. PubMed ID: 11460164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity.
    Kent SJ; Fernandez CS; Dale CJ; Davenport MP
    Trends Microbiol; 2005 Jun; 13(6):243-6. PubMed ID: 15936652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection.
    Brumme ZL; Tao I; Szeto S; Brumme CJ; Carlson JM; Chan D; Kadie C; Frahm N; Brander C; Walker B; Heckerman D; Harrigan PR
    AIDS; 2008 Jul; 22(11):1277-86. PubMed ID: 18580606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill?
    Wick WD; Yang OO; Corey L; Self SG
    J Virol; 2005 Nov; 79(21):13579-86. PubMed ID: 16227278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses against multiple epitopes.
    Nowak MA; May RM; Sigmund K
    J Theor Biol; 1995 Aug; 175(3):325-53. PubMed ID: 7475080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new theory of cytotoxic T-lymphocyte memory: implications for HIV treatment.
    Wodarz D; Page KM; Arnaout RA; Thomsen AR; Lifson JD; Nowak MA
    Philos Trans R Soc Lond B Biol Sci; 2000 Mar; 355(1395):329-43. PubMed ID: 10794051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Waiting times for the appearance of cytotoxic T-lymphocyte escape mutants in chronic HIV-1 infection.
    Liu Y; Mullins JI; Mittler JE
    Virology; 2006 Mar; 347(1):140-6. PubMed ID: 16387340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART.
    Jones LE; Perelson AS
    Bull Math Biol; 2005 Nov; 67(6):1227-51. PubMed ID: 16023709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of CD8+ T-cell response in HIV infection.
    Benito JM; López M; Soriano V
    AIDS Rev; 2004; 6(2):79-88. PubMed ID: 15332430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current status of HIV vaccine development].
    Seki S; Matano T
    Nihon Rinsho; 2008 Oct; 66(10):1965-9. PubMed ID: 18939498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.